Kymera Fortifies Immunology Push with Oral Drugs and $1.6B War Chest

WATERTOWN, MA – February 26, 2026 – Kymera Therapeutics today outlined a year of significant clinical progress and financial fortification, signaling its intent to challenge the status quo in treating immunological diseases. In its full-year 2025 financial report, the clinical-stage biopharmaceutical company detailed major advancements in its pipeline of oral targeted protein degraders (TPD), backed by a formidable $1.6 billion cash position that provides a runway into 2029.

The update centers on the company’s lead candidate, KT-621, a first-in-class oral therapy for atopic dermatitis and asthma that has shown early results comparable to the blockbuster injectable Dupixent. With pivotal trials underway and a second novel drug entering the clinic, Kymera is executing a multi-pronged strategy to deliver a new generation of convenient, oral medicines for chronic conditions affecting millions.

“We set a high bar for what we wanted to achieve in 2025 and exceeded expectations,” said Nello Mainolfi, PhD, Founder, President and CEO of Kymera Therapeutics. “We see an opportunity to change the status quo. With highly encouraging Phase 1b data in atopic dermatitis...KT-621 highlights the opportunity to meaningfully expand the reach to patients who need and deserve treatment, move therapy earlier in the disease journey, and ultimately improve outcomes for millions of patients.”

A New Oral Frontier for Eczema and Asthma

The cornerstone of Kymera’s immunology franchise is KT-621, an oral degrader of the protein STAT6. This transcription factor is a central driver of Type 2 inflammation, the underlying cause of diseases like atopic dermatitis (AD) and asthma. While existing biologics like Dupixent work by blocking the IL-4 and IL-13 signaling pathways from outside the cell, KT-621 works downstream by eliminating the STAT6 protein itself, a mechanism the company believes could offer a more profound and comprehensive blockade.

In December 2025, Kymera reported positive results from its Phase 1b BroADen trial in patients with moderate to severe AD. After just 28 days of once-daily oral dosing, KT-621 demonstrated deep STAT6 degradation in both skin and blood, leading to robust reductions in inflammatory biomarkers. Critically, these molecular changes translated into meaningful clinical improvements. Patients saw an average 63% reduction in the Eczema Area and Severity Index (EASI) score, with significant relief from itch and sleeplessness. The results were compelling enough for the U.S. Food and Drug Administration to grant the drug Fast Track designation.

The company noted that the impact on biomarkers and clinical endpoints was “in line or numerically exceeded data reported from dupilumab studies after 4 weeks of treatment.” While not a head-to-head comparison, the data suggests an oral pill could potentially rival the efficacy of a leading injectable, a disruptive proposition for a market projected to be worth tens of billions of dollars.

Building on this momentum, Kymera has launched two parallel Phase 2b trials. The BROADEN2 study is evaluating KT-621 in approximately 200 adults and adolescents with AD, with data expected by mid-2027. The BREADTH study has begun dosing in about 264 adults with moderate to severe eosinophilic asthma, with results anticipated in late-2027. Success in these trials could pave the way for a therapy that offers patients a more convenient alternative to injections.

Expanding the Pipeline with a “Master Regulator” Target

Beyond its STAT6 program, Kymera is advancing KT-579, a first-in-class oral degrader targeting IRF5, a protein described as a “master regulator of immunity.” Genetically linked to multiple autoimmune diseases like lupus, rheumatoid arthritis (RA), and Sjögren's syndrome, IRF5 has long been considered an “undruggable” target for conventional therapies. Kymera’s TPD platform circumvents this challenge by marking the protein for complete removal.

This month, the company initiated dosing in a Phase 1 clinical trial of KT-579 in healthy volunteers. The study will assess the drug’s safety and its ability to degrade IRF5 in the blood. Preclinical studies have been highly encouraging, showing that KT-579 can effectively block the production of pro-inflammatory cytokines and autoantibodies. In animal models of lupus and RA, the drug’s activity was equal to or more efficacious than currently marketed biologics and small molecules.

The development of KT-579 showcases the breadth of Kymera’s platform and its ambition to tackle complex autoimmune diseases where effective and well-tolerated oral options are desperately needed. Data from the Phase 1 trial is expected in the second half of 2026 and will be a key catalyst for the program.

Financial Firepower and Strategic Leadership

Underpinning these ambitious clinical programs is an exceptionally strong balance sheet. Kymera ended 2025 with $1.6 billion in cash, cash equivalents, and investments, largely due to a successful $692 million equity offering in December. This financial strength provides an operational runway into 2029, a rarity for a clinical-stage biotech that insulates it from market volatility and allows it to fund its pipeline through multiple major inflection points.

This financial stability is necessary to support a growing operational footprint. The company’s research and development expenses rose to $316.6 million in 2025, up from $240.2 million in 2024, reflecting the costs of advancing its late-stage STAT6 program and expanding its discovery efforts. The net loss for 2025 widened to $311.4 million.

Kymera also bolstered its leadership team with the appointment of Dr. Neil Graham as Chief Development Officer. Dr. Graham brings over 30 years of experience, most notably his time at Regeneron, where he was a key leader in the development and successful launch of dupilumab. His direct experience in navigating the complex regulatory and clinical path for a blockbuster immunology drug provides invaluable expertise as Kymera aims to position KT-621 as a market leader.

Validating the Platform Through Key Partnerships

Further validating Kymera's scientific platform are its strategic collaborations with pharmaceutical giants Sanofi and Gilead Sciences. These partnerships not only provide significant non-dilutive funding but also signal big pharma’s confidence in the potential of targeted protein degradation.

Its collaboration with Sanofi is focused on developing IRAK4 degraders for immuno-inflammatory diseases. The program is advancing a next-generation candidate, KT-485/SAR447971, which is expected to enter the clinic in 2026. This partnership has the potential to deliver over $2 billion in milestone payments to Kymera.

Separately, a partnership with Gilead Sciences is aimed at developing oral CDK2 molecular glue degraders for oncology. This collaboration expands Kymera’s TPD expertise into the field of molecular glues and targets breast cancer and other solid tumors. Upon exercising its option, Gilead would assume all development and commercialization responsibilities, with Kymera eligible for significant milestone payments and royalties.

These alliances de-risk Kymera’s strategy by diversifying its pipeline and leveraging the vast resources of its partners. As the company continues to advance its wholly-owned programs like KT-621 and KT-579, it also plans to nominate at least one new development candidate for a first-in-class oral program later this year, ensuring its pipeline remains robust for years to come.